Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17902901 | 0.91 | YTHDC1 (0.79) | YTHDC1ADORA3ADORA1ADORA2AHTR2C | |
| SCHEMBL19010862 | 0.87 | YTHDC1 (0.73) | YTHDC1ADORA3ADORA1ADORA2AHTR2C | |
| SCHEMBL5442351 | 0.85 | YTHDC1 (0.78) | YTHDC1ADORA3ADORA1ADORA2AFLT3 | |
| SCHEMBL7265803 | 0.84 | YTHDC1 (0.73) | YTHDC1ADORA3ADORA1ADORA2AHTR2C | |
| SCHEMBL19049986 | 0.84 | YTHDC1 (1.00) | YTHDC1ADORA3ADORA1ADORA2AHTR2C | |
| SCHEMBL20533808 | 0.82 | YTHDC1 (0.67) | YTHDC1ADORA3ADORA1ADORA2AHTR2C | |
| SCHEMBL29664968 | 0.82 | YTHDC1 (0.67) | YTHDC1ADORA3ADORA1ADORA2AHTR2C | |
| SCHEMBL1713275 | 0.82 | YTHDC1 (0.79) | YTHDC1ADORA3ADORA1ADORA2AFLT3 | |
| SCHEMBL5442056 | 0.81 | YTHDC1 (0.67) | YTHDC1ADORA3ADORA1ADORA2AHTR2C | |
| SCHEMBL16549238 | 0.81 | YTHDC1 (0.77) | YTHDC1ADORA3ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1966210-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071393-A2 | SULPHONAMIDOANILINE DERIVATIVES BEING JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261973-A1 | Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors | GRK4, JAK2, ALK | YTHDC1 4520/4885ADORA3 662/4885ADORA1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.